Daniel joined SEP in 2021 and works principally on deal origination, execution and support, and the financial analysis and assessment of new, growth stage, technology investments.

He was a key member of the deal team which led SEP’s recent investment into drug discovery and design software vendor Cresset.

Daniel joined SEP from global private markets investment firm StepStone Group, where he was a member of the EMEA Private Equity team. Prior to that, Daniel began his career in Investment Banking at Goldman Sachs in London, where he worked on a range of transactions for high growth, technology-enabled, corporate clients.

He is a graduate of the University of Bath and holds a BEng (Hons) in Chemical Engineering.

‍